CHAPTER 20 Opioid Analgesics and Antagonists
Opioids are primarily used for the relief of pain and consequently find widespread application in dentistry. Opioids also possess therapeutically useful antitussive (cough suppressant) and antidiarrheal effects in addition to several undesirable effects, including sedation and somnolence, unwanted constipation, nausea and vomiting, respiratory depression, and urinary retention. Repeated use of opioids for control of pain can lead to analgesic tolerance and physical and sometimes psychological dependence. These shortcomings notwithstanding, no other drugs are more efficacious as analgesics than opioids. Three groups of opioid agents are discussed in this chapter: pure agonists, pure antagonists, and agonist-antagonists, which are compounds that in the same molecule possess agonist and antagonist properties. Drugs that are pure agonists and those that are mixed agonist-antagonists are used principally for relief of pain; pure antagonists prevent or reverse the effects of pure agonists and mixed agonist-antagonists and are used principally to reverse opioid intoxication.
Morphine, the prototypic opioid analgesic, and codeine are natural phenanthrene alkaloids contained in opium, which is derived from the poppy plant Papaver somniferum. The unripe seed capsules of the plant are incised, and the milky exudate is collected, dried, and powdered. Opium powder contains 5% to 20% morphine and 0.5% to 2.5% codeine, depending on the source, and many other alkaloids. None of the other alkaloids is therapeutically useful in pain control; one constituent, papaverine, has been used as a smooth muscle relaxant.
The first documented descriptions of Papaver somniferum appeared in approximately 1550 bc in the Ebers papyrus of ancient Egypt.35 Later, in the third century bc, writings of the Greek philosopher Theophrastus contained references to poppy juice. The active analgesic and constipative principle of the poppy plant was not isolated, and the drug was not named (after Morpheus, the Greek god of sleep) until 1806, when Sertürner first isolated morphine from opium and described its properties. Currently available opioid analgesics in addition to morphine and codeine are either semisynthetic congeners of morphine (e.g., hydromorphone, oxymorphone, hydrocodone, and oxycodone) or entirely synthetic (e.g., meperidine, fentanyl, methadone, and propoxyphene).
The mechanisms by which opioids act at specific central nervous system (CNS) and peripheral sites to produce their effects are fairly well understood. In the early 1970s, binding sites in the CNS were discovered that stereospecifically, saturably, and reversibly combined with opioids.37 These receptors were later shown to be the natural effectors of opioid action; that is, specific pharmacologic effects were produced by binding of opioids to these receptors. The discovery of opioid receptors naturally raised questions about their biologic significance, spurring research that led to the discovery of endogenous opioid receptors and peptides. Subsequently, several families of endogenous opioid peptides and numerous opioid receptors have been characterized.
There are four families of endogenous opioid peptides: endomorphins, endorphins, enkephalins, and dynorphins. Figure 20-1 illustrates their biologic derivations and structural relationships. The pentapeptide enkephalins—methionine-enkephalin (met-enkephalin) and leucine-enkephalin (leu-enkephalin)—were the first endogenous opioids to be discovered.13 These peptides were subsequently shown to be potent opioid receptor agonists in the same biologic systems in which morphine is active. Initially, the enkephalins were thought to be derived from a larger 91-amino acid peptide, β-lipotropin, but it is now clear that β-lipotropin gives rise to a separate group of opioid peptides, the endorphins (see later).
FIGURE 20-1 Derivations and structures of endogenous opioids. A, Endorphins. Proteolysis products of the pituitary hormone β-lipotropin (β-LPH), endorphins are ultimately derived from the precursor molecule pro-opiomelanocortin. Other peptides of biologic importance obtained from pro-opiomelanocortin include adrenocorticotropin (ACTH), γ-lipotropin (γ-LPH), and several melanotropins (not shown). The initial amino acid sequence of β-endorphin is shown (at bottom left) to illustrate its structural relationship to the enkephalins and dynorphins; the numbers refer to amino acid residues of β-LPH. B, Enkephalins. In addition to met-enkephalins and leu-enkephalins, proenkephalin may give rise to at least two other biologically active molecules, a heptapeptide and an octapeptide, both of which contain met-enkephalin as part of their structure. C, Dynorphins. A common precursor, prodynorphin, yields several dynorphins, including dynorphin A(1-17) (shown here), dynorphin A(1-8), dynorphin B(1-13), and at least two other peptides, α-neoendorphin and β-neoendorphin. D, Endomorphins. The precursor for these two endogenous opioid peptides is unknown.
Endomorphin-1 and endomorphin-2 are newly discovered endogenous opioid peptides.47 Both are short tetrapeptides (NH2-Tyr-Pro-Trp/Phe-Phe-CONH2) and structurally distinct from the other opioid peptides (see later). The endomorphins have been localized to areas in the CNS associated with pain processing (e.g., spinal dorsal horn, trigeminal nucleus, midbrain periaqueductal gray) and in the endings of sensory neurons that terminate in the spinal dorsal horn. Although the genes for the endorphins, enkephalins, and dynorphins are known, the gene for the endomorphins has yet to be isolated.
The precursor of the enkephalins, proenkephalin, is present in the CNS and the adrenal medulla. Although proenkephalin in the brain is similar, if not identical, to proenkephalin in the adrenal medulla, processing of the large precursor polypeptide differs in the two locations. In the brain, cleavage of proenkephalin is generally more complete, and free enkephalins are the predominant products (four copies of met-enkephalin, one copy of leu-enkephalin, and one copy each of a heptapeptide and an octapeptide). In the adrenal medulla, large enkephalin-containing polypeptides predominate.
Prodynorphin is the common precursor for several larger opioid peptides, three dynorphins and two neoendorphins, all of which share with the enkephalins the same N-terminal amino acid sequence: NH2-Tyr-Gly-Gly-Phe-Met/Leu. The products of prodynorphin are often found in association with the enkephalins within the CNS.
The endorphins are a group of endogenous peptides that are larger in size and are distributed differently in the CNS than the endomorphins, enkephalins, or dynorphins. The precursor for the endorphins, pro-opiomelanocortin, gives rise to several important hormones, including adrenocorticotropic hormone and β-lipotropin, which are further processed to form biologically active products. The most important opioid derived from β-lipotropin is β-endorphin, the 30-amino acid carboxy terminal sequence of β-lipotropin. Shorter cleavage products of β-endorphin, such as α-endorphin and γ-endorphin, have been isolated from the pituitary, but their function is uncertain.
Sites in the CNS where opioid peptides are located differ for the different peptides, confirming that they are involved in different functions. It is a mistaken impression that all opioid peptides in all locations are involved in the modulation of pain. Neurons containing endomorphins are not as widely distributed in the CNS as neurons containing other opioid peptides, but endomorphins are located in pain-processing areas where they are considered to function as neurotransmitters that act at opioid receptors. Neurons containing enkephalins are widely distributed throughout the brain (e.g., striatum, limbic system, midbrain, and medulla) and the spinal cord where they, too, are considered to function principally as neurotransmitters.22 Prodynorphin-derived peptides are abundant in the pituitary, hypothalamus, midbrain, and striatum. Differential processing of proenkephalin and prodynorphin in various brain areas leads to different products having different functions.
The endomorphins, enkephalins, and dynorphins are stored in nerve terminals and are quickly destroyed by peptidases (aminopeptidase N [EC 188.8.131.52] and neutral endopeptidase [EC 184.108.40.206]) when released. β-Endorphin is present in high concentrations in the intermediate lobe of the pituitary and in neurons in the mediobasal hypothalamus, whose axons terminate in the amygdala, periaqueductal gray matter, and brainstem. β-Endorphin coexists with adrenocorticotropic hormone in pituitary secretory granules, and both peptides can be released simultaneously. β-Endorphin is believed to function more as a neurohormone than as a neurotransmitter, mediating diverse autonomic and psychological responses to pain and stress.
Three opioid receptors have been cloned: mu (μ), kappa (κ), and delta (δ) (Table 20-1).15,32 They share considerable structural homology (approximately 60% to 65%), contain seven membrane-spanning α-helical segments, and are coupled to transducing G proteins (Figure 20-2). G proteins couple opioid receptors to intracellular effectors and exist as heterotrimers; there is structural and functional diversity in the three G protein subunits. Each heterotrimer consists of an α subunit isoform (of which there are at least 18) and a dimer of β-γ subunits (which also exist in multiple isoforms) that link with specific (and potentially diverse, given the numbers of isoform combinations that are possible) effector systems. Specifically, opioid receptors couple in this way with adenylyl cyclase and ion channels to reduce neurotransmitter release (see later).
FIGURE 20-2 Diagram of a G protein–coupled opioid receptor. Opioids bind within the hydrophobic membrane-spanning domains of the receptor. Opioid agonist effects at the receptor are mediated by G proteins, an α subunit associated with guanosine diphosphate (GDP), and a β-γ dimer. When an opioid agonist binds, the conformation of the receptor is changed as the membrane-associated G proteins assemble with the receptor. GDP is exchanged with guanosine triphosphate, and this activated Gα complex negatively regulates adenylyl cyclase. The β-γ dimer activates conductance in a G protein inwardly rectifying K+ (GIRK) channel and inhibits voltage-gated Ca++ channels (VGCC) in the cell membrane. (See Chapters 1 and 5 for more details on signal transduction.) ATP, Adenosine triphosphate; cAMP, cyclic 3′5′-adenosine monophosphate.
The amino acid sequences of the three opioid receptors are most homologous in the transmembrane domains and intracellular loops; the sequences share little homology in the extracellular loops and N- and C-termini. Each receptor is distributed differently in the CNS, peripheral nervous system, and smooth muscle of the gastrointestinal tract. A receptor with high sequence homology to the three cloned opioid receptors, termed ORL-1 (for opioid receptor–like, an “orphan” receptor), has been discovered.21,33 Despite its structural similarity to opioid receptors, opioids do not bind to ORL-1 with high affinity. A heptadecapeptide termed orphanin FQ (or nociceptin), which is structurally similar to the endogenous opioid peptide dynorphin, seems to be the endogenous ligand for ORL-1 (which has been renamed the N/OFQ receptor [NOP]). Nociceptin does not act at any of the three cloned opioid receptors, however, and the nociceptin–NOP ligand–receptor complex may instead function to facilitate pain at some sites.
Another heptadecapeptide, termed nocistatin, is also derived from the same gene that gives rise to nociceptin. Nocistatin is reported to “block” the effects of nociceptin, but nocistatin does not displace nociceptin from its receptor (ORL-1),26 indicating that the opposing effects of nocistatin are produced at a yet to be identified receptor.49 It is believed now that nocistatin exerts an inhibitory effect through a presynaptic Gi/Go-coupled receptor not related to either the opioid receptors or the NOP receptor.5
The μ receptor is the site at which all the currently available pure agonists act to produce analgesia. Morphine and other similar pure agonists have greatest affinity for μ receptors in the CNS and peripheral nervous system and lower affinity for δ and κ receptors. Among the endogenous opioid peptides, the endomorphins have the highest affinity for the μ receptor; β-endorphin and the enkephalins also exert some of their effects at μ receptors. Two subtypes of μ receptor have been characterized by pharmacologic means: μ1, which is associated with supraspinal analgesia, and μ2, which subserves spinal analgesia, respiratory depression, and gastrointestinal actions. Pharmacologic studies have also implied the existence of two subtypes of δ receptor, at which the endogenous enkephalins are considered to be the prototypic agonists, although the enkephalins also interact with μ receptors. The δ receptor is also involved in analgesia, mainly through spinal mechanisms, and in causing, along with μ receptors, opioid reinforcement (see Chapter 51).
Dynorphins, representing the third class of endogenous opioid peptides, have been proposed to be ligands for the κ receptor, of which three subtypes have been characterized pharmacologically. Two κ receptors mediate spinal (κ1) and supraspinal (κ3) analgesia and are principally responsible for the analgesic effects of the mixed agonist-antagonist group of opioid analgesics currently available. Although the endomorphins selectively bind to the μ opioid receptor,48 other endogenous opioids and clinically available drugs do not bind selectively to specific opioid receptors. Although morphine and other pure agonists preferentially bind at μ receptors, they can produce effects at δ and κ opioid receptors as well, particularly as the dosage is increased.
Despite pharmacologic evidence for the existence of multiple subtypes of opioid receptors, only one of each opioid receptor has been cloned. There is no evidence at present for the existence of genes other than those that give rise to the already cloned μ, δ, and κ receptors. It is possible that not all opioid receptor genes have been cloned, but molecular mechanisms and other factors most likely explain the pharmacologic diversity of effects produced by various ligands at opioid receptors. Receptor isoforms may be produced by alternative splicing in the coding regions of the three cloned opioid receptors.7 Variant mRNAs have been reported for all three opioid receptors, although their expression is typically very low, and it is not clear that splice variants can be distinguished pharmacologically. It seems more likely that other mechanisms (e.g., post-translational regulation, variable activation of receptors by different ligands, receptor dimerization, intracellular interactions with proteins associated with different effectors) explain the pharmacologic diversity of opioid receptor subtypes. Many G protein–coupled receptors exist as dimers (two receptors linked), and heterodimerization of δ and κ receptors could result in a complex pharmacologic profile.
The sigma (σ) receptor, initially considered to be an opioid receptor, is now known to mediate the dysphoric and psychotomimetic effects of opioids and those of phencyclidine, a nonopioid hallucinogen. This phencyclidine receptor has been identified as an inhibitory component of the N-methyl-d-aspartate receptor complex, which modulates opioid tolerance and dependence.
Much remains to be learned about the physiologic roles of the endomorphins, enkephalins, dynorphins, and endorphins. It is established that enkephalins, present principally in local circuits or interneurons in the CNS, have an inhibitory effect on other cells. Endogenous opioids tonically modulate the secretion of gonadotropins from the pituitary. When the opioid receptor antagonist naloxone is administered to normal subjects, the plasma concentrations of luteinizing hormone and follicle-stimulating hormone are increased because naloxone releases hypothalamic neurons from a tonic endogenous opioid inhibition.
Considerable attention has been given to the notion that endogenous opioid peptides tonically modulate nociception (pain). One would expect occupation of opioid receptors by naloxone to prevent any action by endogenous opioid peptides and lower the response threshold for pain if endogenous opioids tonically modulated nociception. A number of studies have shown that the administration of naloxone to normal human volunteers does not affect their resting pain thresholds or responses to experimental pain stimuli. In other situations, naloxone has been reported to attenuate the analgesic effects of acupuncture and of placebo administration after minor oral surgery and to be hyperalgesic in humans after major surgery.31 From these and other findings,8 it seems that endogenous antinociceptive opioid systems are normally quiescent but can become physiologically active and affect pain processing when significant injury or stress is present. It seems that endogenous opioid activity can be enhanced by the anticipation of pain relief, producing naloxone-reversible placebo effects that diminish the perception of pain (i.e., elicit analgesia).6
Among the many effects of opioids, analgesia has been most thoroughly studied. We now know that opioids acting at opioid receptors in the periphery and at spinal and supraspinal sites can produce clinically effective analgesia. Knowledge of the central sites of opioid action came first; documentation of direct peripheral analgesic actions of opioids is relatively recent.38
Early investigators attempted to determine the central locus of morphine’s analgesic action by administering morphine directly into selected brain sites. These studies succeeded in identifying an area of the brainstem surrounding the cerebral aqueduct as a site important to morphine analgesia. Corollary studies found that electrical stimulation of this same area in the midbrain in animals and humans produced a potent, long-lasting analgesia partially mediated by endogenous opioids.11 Morphine and other opioid agonists acting at this site produce analgesia by engaging a descending system of pain inhibition.8
As illustrated in Figure 20-3, information about pain from nociceptors—that is, peripheral receptors in skin, muscle, joints, and viscera that respond to pain-producing stimuli—can be influenced at the first central synapse (spinal or medullary dorsal horn) by this descending system of pain inhibition. It is important to appreciate two features of this pain-modulating system: the descending pathway from the midbrain is indirect (there is a synaptic relay in the medulla or the dorsolateral pons or both), and although engaged by an opioid acting at opioid receptors in the midbrain, the neurotransmitters in the spinal cord or medullary dorsal horn that ultimately inhibit pain transmission are nonopioids such as 5-hydroxytryptamine (5-HT, serotonin) and norepinephrine.8 Engagement of the descending pain inhibitory circuit is also responsible for placebo-induced analgesia.
FIGURE 20-3 Descending pain-modulating pathways from the brainstem to the spinal cord. Descending influences, whether activated in the midbrain periaqueductal gray (PAG) or rostroventral medial medulla (RVM) by endogenous or exogenous opioids (*) or stimulation, are mediated at the level of the spinal cord by noradrenergic and serotonergic receptors.
A second means by which morphine and other opioid agonists modulate pain is by acting at opioid receptors in the brain at sites not associated with activation of the descending pain inhibitory system. Actions of opioids at these brain sites do not affect the response threshold to a painful stimulus but rather influence the interpretation of and emotional reaction to the stimulus.31 This so-called motivational-affective component of the response to pain is discussed later in this chapter.
A final means by which morphine and other opioid agonists produce analgesia is by acting at opioid receptors located on the peripheral and central terminals of nociceptors. Opioid receptors are located on the terminals of these specialized nerve fibers, typically Aδ and C fibers, which connect the periphery directly with the CNS. Analgesic effects of opioids can be produced by direct administration of an opioid into a joint or, more commonly, the epidural or intrathecal space.46
Opioids can act at several sites, each of which can contribute independently to the analgesia produced. When given systemically, opioids have access to all potential sites of action, and the analgesia produced is likely a product of peripheral, spinal, and supraspinal interactions with opioid receptors. These mechanisms are likely to be synergistic resulting in increased opioid potency and, consequently, reduced toxicity. This knowledge can be used to improve pain control and limit the incidence or severity of undesirable opioid effects. Because pain modulation descending from the brainstem is mediated in the spinal cord by norepinephrine and 5-HT, the direct effects of an opioid given into the epidural space can be enhanced by epidural administration of an α-adrenoceptor agonist such as clonidine.24
Tricyclic antidepressants, which block the reuptake of norepinephrine and 5-HT, are also effective adjuvants (although antidepressants such as amitriptyline also possess analgesic efficacy unrelated to their effects on monoamine reuptake). This strategy allows reduction of the dose of opioid without compromising the analgesia produced. Two drugs, tramadol and tapentadol, produce analgesic actions by engaging multiple mechanisms, including activity at the opioid receptors and inhibition of reuptake of norepinephrine or serotonin or both. By requiring less opioid for adequate pain control, undesirable opioid effects, such as urinary retention, respiratory depression, sedation, and development of analgesic tolerance, can be reduced. It has also been documented that administration of very low doses of morphine directly into the knee joint after arthroscopic knee surgery can control postoperative pain.38
The mechanisms by which opioids produce their effects are best established for direct actions at opioid receptors located on neurons. Actions commonly produced at all three opioid receptors include inhibition of adenylyl cyclase, inhibition of Ca++ conductance, activation of K+ conductance, and inhibition of neurotransmitter release (see Figure 20-2). Acute inhibition of adenylyl cyclase by an opioid leads to a decrease in intracellular cyclic 3′,5′-adenosine monophosphate, decreasing an inward, nonselective cation current and decreasing cell excitability. All three opioid receptors also activate a G protein inwardly rectifying K+ conductance and inhibit voltage-activated Ca++ currents, both events mediated by G protein β-γ subunits. Because Ca++ influx is required for the stimulus-secretion coupling of neurotransmitter release, opioids decrease the release of excitatory neurotransmitters, such as glutamate, substance P, and calcitonin gene–related peptide, from nociceptor terminals and attenuate the transmission of nociceptive information at the first central synapse. Because opioids activate this G protein–rectifying K+ conductance, they produce a relative hyperpolarization of neurons, making them more difficult to excite.
The structure of morphine is shown in Figure 20-4. Morphine is the prototypic opioid analgesic (pure agonist) and the one about which most is known. Morphine is widely used for pain control and can be given by virtually any route of administration. All opioid analgesics share with morphine the ability to produce analgesia, respiratory depression, constipation, gastrointestinal spasm, and physical dependence; none has yet been shown to be significantly different from or superior to morphine regarding its important pharmacologic features. The incidence of untoward effects (e.g., respiratory depression) and the intensity of action of pure agonists are qualitatively similar and differ little when compared at doses that produce equivalent analgesia. Consequently, morphine is discussed in greater detail than other opioid analgesics, and what is stated for morphine applies in general to other pure agonists. Significant differences that exist between morphine and other opioids are mentioned as each individual agent is discussed.
The CNS effects of morphine are a combination of stimulation and depression and include analgesia, drowsiness, euphoria-dysphoria, respiratory depression, suppression of the cough reflex, pupillary constriction, suppression of the secretion of some (luteinizing hormone) and enhancement of other (prolactin) pituitary hormones, and initial stimulation of the medullary chemoreceptor trigger zone for emesis followed by depression of vomiting.
The analgesia produced by morphine and other pure agonists occurs without loss of consciousness. When opioids are administered for relief of pain (or for a cough or diarrhea), they provide only symptomatic relief without alleviation of the cause of the pain (or cough or diarrhea). The analgesia produced by opioid analgesics is dose-dependent and selective in that other sensory modalities (e.g., vision, audition) are unaffected at therapeutic doses. The standard parenteral analgesic dose of morphine, 10 mg/70 kg of body weight, is considered a therapeutic dose for relief of moderate-severe pain. Because pain is a highly subjective and personal experience, however, adequate pain relief is best achieved by titrating the dose to the needs of the patient.
As already discussed, the sites of opioid-produced analgesia include the periphery and spinal and supraspinal brain areas. It is generally accepted that opioid-induced analgesia involves the sensory-discriminative and motivational-affective components of pain. The sensory-discriminative component of pain is associated with identification and localization of the source of pain, whereas the motivational-affective component of pain is related to one’s reaction to pain.33 Pain is not a simple sensation associated with a single pain pathway from the periphery to the cortex, but rather, it is a complex experience that can be influenced by the environment in which the pain arises: prior experience and expectation; attention, anxiety, mood, and stress levels; and other societal, emotional, and cognitive contributions. The nociceptive component of pain may not be as much affected by opioid analgesics as is the reaction to pain. A common report from patients after receiving an opioid for relief of pain is that the pain is still present, but that it is not discomforting. Clinical impressions and patients’ reports suggest a prominent action by opioid analgesics on the motivational-affective component of pain, presumably resulting from opioid actions at opioid receptors within the limbic system of the brain.
An additional significant feature of opioid analgesics is that they are generally more effective against continuous, dull, aching pain than sharp, intermittent pain. It is also known that sensitivity to pain and the ability to clear morphine decrease with age, whereas the elimination half-life of morphine increases with age; the pain relief provided by morphine typically increases with age.14,28
Morphine and its congeners depress respiration in a dose-related fashion. Respiratory depression represents the principal undesirable, potentially life-threatening effect of opioids as a group. Opioids are capable of depressing the tidal volume and the rate of respiration. In humans, morphine decreases the response of brainstem respiratory centers to the carbon dioxide tension of the blood. It also significantly depresses pontine and medullary centers that regulate respiratory frequency.2 Irregular rhythms and periodic breathing are common after toxic doses of morphine or its congeners, and the normal respiratory rate of 16 to 18 breaths/min may be reduced to 3 to 4 breaths/min. All currently available opioid analgesics are capable of depressing respiration in a manner similar to that of morphine when administered in doses that produce equal analgesia.
Morphine and other pure agonists are effective antitussives; codeine is widely used in cough preparations for this purpose. Morphine itself is not commonly used as a cough suppressant. Opioids exert their antitussive effect by depressing an area in the brainstem. Although the brainstem sites for the respiratory depressant and antitussive effects of opioids are anatomically close, there is no apparent relationship between opioid depression of one or the other because suppression of the cough reflex occurs at opioid doses lower than those required to produce an analgesic effect or to depress respiration.
At therapeutic doses, morphine and most of its congeners produce pupillary constriction (miosis) in humans. The emphasis on humans is significant because in some other species, such as cats, in which opioids exert primarily an excitatory effect, the pupils are dilated by morphine. The miosis produced by opioids results from a central effect mediated by the oculomotor nerve and not from a direct action on the circular or radial muscles of the iris of the eye. Although tolerance to opioids has not yet been discussed, it is appropriate to indicate here that tolerance to the pupillary-constricting effect of morphine and some other opioids does not develop to any appreciable extent. Consequently, long-term users of morphine and heroin continue to have constricted pupils, although they likely will have developed tolerance to many other opioid effects.
Opioids directly stimulate the chemoreceptor trigger zone in the medulla and can produce emesis. Opioids are commonly given before, during, and after surgery, and nausea and vomiting are highly undesirable. After the initial period of stimulation, however, opioids depress the brainstem medullary center for vomiting. This subsequent depression occurs at therapeutic concentrations and is virtually total; other opioid analgesics or emesis-inducing agents administered during this time are generally ineffective in causing emesis. There is also apparently a vestibular component to the nausea produced by morphine and its congeners because nausea occurs more frequently in ambulatory than in recumbent patients.
Morphine exerts important influences on smooth muscle tone that have therapeutic and toxic implications. The drug also affects gastrointestinal activity by reducing glandular secretions and by promoting absorption of fluid from the gastrointestinal lumen.
The use of opium for relief of diarrhea and dysentery antedated by centuries the use of opium for relief of pain. Opioids exert significant effects on smooth muscle all along the gastrointestinal tract. The overall action of morphine and its congeners is constipating, an effect that is useful therapeutically. Opioid analgesics, acting principally at opioid receptors in the gastrointestinal tract but also at opioid receptors in the CNS,41 increase smooth muscle tone and decrease propulsive motility throughout the gastrointestinal tract. In the large intestine, muscle spasms can result from the marked increase in muscle tone and nonpropulsive muscle contractions. Spasm of the smooth muscle of the biliary tract, which can be very painful, can also occur after the administration of therapeutic doses of morphine and related drugs.
Morphine and other pure agonists delay gastric emptying. In addition, gastric acid secretion is usually depressed, and pancreatic, biliary, and intestinal secretions are routinely depressed by opioid administration. Inhibiting intestinal hypersecretion and promoting reabsorption are important contributors to the beneficial effect of morphine in the treatment of diarrhea.
Morphine and other pure agonists also increase muscle tone in smooth muscle of organs other than those of the gastrointestinal tract, such as the ureters, urinary bladder, uterus, and bronchioles, but at therapeutic doses the effect of opioids on these muscles is generally unremarkable. Urinary retention, characterized by urgency and increased tone of the bladder sphincter, is common after all routes of opioid administration. In addition to effects on tone and contractility of smooth muscle, opioids also possess antidiuretic effects. Although opioids increase uterine tone, they do not generally influence the duration of labor. Likewise in the bronchial musculature, opioids administered at usual therapeutic doses do not produce significant bronchoconstriction, even though they may aggravate an asthmatic condition or precipitate an asthmatic attack resulting in part from histamine release.
In large doses, opioid effects on all these smooth muscles may be significant. Contraction of the ureter contributes to cessation of urine flow; increased uterine tone significantly prolongs labor and may increase neonatal morbidity rates; and bronchoconstriction occurs.
The effects of morphine and other pure agonists on blood pressure, heart rate, and cardiac work are generally minor at analgesic doses. The vasomotor center of the medulla is relatively unaffected by opioid analgesics, and blood pressure is maintained near normal even after intoxicating doses of opioids. The decrease in blood pressure observed during acute opioid intoxication is primarily caused by hypoxia that results from opioid-induced respiratory depression.